Evaluation of active inflammation, chronic structural damage, and response to treatment of sacroiliitis in axial spondyloarthritis using the Spondyloarthritis research consortium of Canada scoring system

• Published in: BMC musculoskeletal disorders 2022-07, Vol.23 (1), p.1-654, Article 654
• Main Authors: Zhang, Yimeng, Guo, Zikang, Zhan, Ying, Qu, Jin, Lei, Xinwei
• Format: Article
• Language: English
• Subjects: Ankylosing spondylitis; Arthritis; Axial spondyloarthritis; Bone marrow; C-reactive protein; Care and treatment; Consortia; Diagnosis; Edema; Erythrocyte sedimentation rate; Evaluation; Inflammation; Inflammatory diseases; Joint diseases; Magnetic resonance imaging; Metaplasia; Musculoskeletal diseases; Patients; Rheumatic diseases; Rheumatoid arthritis; Sacroiliac joint; Sacroiliitis; Spondyloarthritis research consortium of Canada; Statistical analysis; Treatment response; Tumor necrosis factor-TNF; Tumor necrosis factor-α
• ISSN: 1471-2474; 1471-2474
• DOI: 10.1186/s12891-022-05609-x

Background Axial spondyloarthritis (axSpA) is a chronic inflammatory rheumatic disease affecting the spine and sacroiliac joints. To investigate whether there are differences in inflammatory and chronic structural damages, as assessed by a semiquantitative MRI scoring method, between non-radiographic axial spondyloarthritis (nr-axSpA) and ankylosing spondylitis (AS) patients with active inflammation at baseline, and to evaluate the treatment response in these patients after 3 months of tumor necrosis factor-alpha (TNF-[alpha]) inhibitor treatment. Methods Fifty-eight axSpA patients with active inflammation were included in the study. The patients were divided into nr-axSpA group and AS group. MRI examinations of the sacroiliac joints were performed before and after treatment. Inflammatory and structural damages in these patients were assessed using the established Spondyloarthritis Research Consortium of Canada (SPARCC) inflammation and sacroiliac joint structural (SSS) scoring methods, which are two MRI-based scoring methods. The SPARCC score, SSS score, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) level were compared between the two groups. Results At baseline, SPARCC scores for patients in the nr-axSpA and AS groups did not differ significantly (P > 0.05); however, SSS scores for fat metaplasia, erosion, and backfill for patients in the AS group were significantly higher (P < 0.001). Compared with baseline, SPARCC scores were significantly decreased in both groups after treatment (P < 0.001); however, after treatment, no statistically significant difference was found regarding SPARCC scores between the AS and nr-axSpA groups. Compared with baseline, a significant increase in the SSS scores for fat metaplasia and backfill (P < 0.001) and a significant decrease in the SSS scores for erosion (P < 0.001) were observed in all axSpA patients. Changes in the SPARCC score was inversely correlated with the changes in the SSS score for fat metaplasia (r = - 0.634, P < 0.001). Changes in the SSS score for backfill were positively correlated with the changes in the SSS score for fat metaplasia (r = 0.277, P < 0.05) and inversely correlated with those for erosion (r = - 0.443, P < 0.001). Conclusion The SPARCC and SSS scoring systems can be used to assess inflammatory and chronic structural damages as well as treatment responses in patients with axSpA. More severe structural damages were seen in AS patients. TNF-[alpha] inhibitor treatment for